Divis Labs Q4 net seen up 10%, generic biz may support topline

Topline growth may be on the back of increased capacity utilisation at new SEZ units and generic business. Analysts feel capacity utilisation rates should rise to 80 percent against 75 percent earlier.

May 27, 2016 / 17:39 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Pharma firm Divis Laboratories' fourth quarter profit is seen rising 10 percent to Rs 269 crore and revenue may increase 13 percent to Rs 923.65 crore compared to year-ago period, according to average of estimates of analysts polled by CNBC-TV18. Earnings will be announced on May 28.

Topline growth may be on the back of increased capacity utilisation at new SEZ units and generic business. Analysts feel capacity utilisation rates should rise to 80 percent against 75 percent earlier.

Operating profit (EBITDA - earnings before interest, tax, depreciation and amortisation) is likely to rise 12 percent to Rs 351.6 crore but margin may remain at 38 percent YoY due to favourable business mix.

first published: May 27, 2016 05:39 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347